Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine-Reference-Cited by-全球学者库

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Published:2021-02-04 Issue:5 Volume:384 Page:403-416
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Baden Lindsey R.¹,El Sahly Hana M.¹^ORCID,Essink Brandon¹,Kotloff Karen¹,Frey Sharon¹,Novak Rick¹,Diemert David¹,Spector Stephen A.¹,Rouphael Nadine¹,Creech C. Buddy¹,McGettigan John¹,Khetan Shishir¹,Segall Nathan¹,Solis Joel¹,Brosz Adam¹,Fierro Carlos¹,Schwartz Howard¹,Neuzil Kathleen¹,Corey Lawrence¹^ORCID,Gilbert Peter¹,Janes Holly¹,Follmann Dean¹,Marovich Mary¹,Mascola John¹,Polakowski Laura¹,Ledgerwood Julie¹,Graham Barney S.¹,Bennett Hamilton¹,Pajon Rolando¹,Knightly Conor¹,Leav Brett¹,Deng Weiping¹,Zhou Honghong¹,Han Shu¹,Ivarsson Melanie¹,Miller Jacqueline¹,Zaks Tal¹

Affiliation:

1. From Brigham and Women’s Hospital (L.R.B.), Boston, and Moderna, Cambridge (H.B., R.P., C.K., B.L., W.D., H.Z., S.H., M.I., J. Miller, T.Z.) — both in Massachusetts; Baylor College of Medicine (H.M.E.S.) and Centex Studies (J.S.) — both in Houston; Meridian Clinical Research, Savannah (B.E., S.K., A.B.), and Emory University (N.R.) and Atlanta Clinical Research Center (N.S.), Atlanta — all in Georgia; University of Maryland School of Medicine, Baltimore (K.K., K.N.), and National Institute of Allergy and...

Funder

National Institute of Allergy and Infectious Diseases

Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa2035389

Cited by 7719 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A qualitative study evaluating COVID-19 vaccine hesitancy among individuals living in Mississippi;SSM - Qualitative Research in Health;2024-06

2. Evaluating length of immune response to SARS-CoV2 vaccine: A cohort review of spike protein antibody titer after vaccination;Clinical Immunology Communications;2024-06

3. Evolution of the structure of lipid nanoparticles for nucleic acid delivery: From in situ studies of formulation to colloidal stability;Journal of Colloid and Interface Science;2024-04

4. The impact of corona virus disease-2019 (COVID-19) vaccination on patients with systemic rheumatic diseases attending a tertiary care university-based hospital;The Egyptian Rheumatologist;2024-04

5. Systematic development of ionizable lipid nanoparticles for placental mRNA delivery using a design of experiments approach;Bioactive Materials;2024-04